Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs.
about
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitisThe genetic basis of ankylosing spondylitis: new insights into disease pathogenesisInvolvement of Notch1/Hes signaling pathway in ankylosing spondylitis.Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012.Indirect comparisons of the efficacy of biological agents in patients with active ankylosing spondylitis: a systematic review and meta-analysis.Developments in the scientific and clinical understanding of the spondyloarthritidesCurrent therapeutics for spondyloarthritis.Active axial spondyloarthritis: potential role of certolizumab pegol.The effects of β-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte/macrophage, J774 cell line.Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials.Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study.Axial spondyloarthritis: is there a treatment of choice?Have the annual trends of total knee arthroplasty in ankylosing spondylitis patients decreased?Preclinical and pharmacotoxicology evaluation of α-l-guluronic acid (G2013) as a non-steroidal anti-inflammatory drug with immunomodulatory property.Managing morbidity and treatment-related toxicity in patients with ankylosing spondylitis.Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis.Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population.Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS).[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures].[Diagnosis and therapy of axial spondyloarthritis including ankylosing spondylitis (Bechterew's disease)].[Early therapy of axial spondyloarthritis and relevance of radiological progression].Inflammation, new bone formation and treatment options in axial spondyloarthritisThe current standard of care and the unmet needs for axial spondyloarthritis
P2860
Q26774173-EF32E53A-9A75-4F65-95C4-55AC5C754D39Q33806334-50812ECB-AAE8-4230-AE3E-9D114871797BQ35632152-3345E739-A2BB-4DE7-BB26-37C9A1066589Q36182303-60432A3B-D5AA-4943-97E8-39D27A85B2D4Q36383550-0405CF50-0D93-462D-9F6E-BE2112A1D4E8Q37207018-B73553FF-0076-4710-A8A9-F8EB2CAC594DQ37944297-BC5069E9-557D-43B1-B950-E3ED0059D2B7Q38194547-EFCDF3B5-0BCF-4E0C-8FAF-DF167B860CDAQ38371958-A9BFCA19-77B6-4C77-9C25-8CC02D47AE38Q38561891-64E37646-FC1C-43B7-BC5D-65735178E1AEQ38787301-444E13B4-BD53-4B0D-B8B8-2BF5D38409AAQ42013856-0CB7AA41-A2B4-4A7F-BEDA-D24A839B1FB5Q47104824-E693B7AE-A08A-4EA9-A6D7-5D036A0115BFQ47873864-49B15134-4D8A-4A55-BC73-3B58D7C0F3E2Q48641283-A9898C96-E1CA-4DFC-9D53-A38D28198E79Q51037569-9E5F90DC-5E04-4F42-90C8-0389D5120C26Q51661761-135F5A10-EBCC-4030-B39F-B215F8123E5EQ52863510-78E7E014-ED23-42E2-B225-5B5891E08651Q52874129-7F67512F-94B3-4A80-85F7-AECA23E01E40Q52887701-A08CE7D6-7DA7-4F33-AC5B-35A45C584647Q52889934-0481CC0B-C029-446F-8F05-1D4F2F3D1EAAQ56964033-5C031579-AB6E-4A9C-A66C-BA4AD1DB911EQ59134860-97637145-17AC-4A37-89D1-951139E22749
P2860
Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Benefits and risks of ankylosi ...... roidal antiinflammatory drugs.
@en
Benefits and risks of ankylosi ...... roidal antiinflammatory drugs.
@nl
type
label
Benefits and risks of ankylosi ...... roidal antiinflammatory drugs.
@en
Benefits and risks of ankylosi ...... roidal antiinflammatory drugs.
@nl
prefLabel
Benefits and risks of ankylosi ...... roidal antiinflammatory drugs.
@en
Benefits and risks of ankylosi ...... roidal antiinflammatory drugs.
@nl
P2093
P356
P1476
Benefits and risks of ankylosi ...... eroidal antiinflammatory drugs
@en
P2093
P2860
P304
P356
10.1002/ART.23275
P577
2008-04-01T00:00:00Z